These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 8506753

  • 1. Immunotherapy by a slow delivery system of interleukin-2 in mice models.
    Matsuoka J, Sakagami K, Fujiwara T, Onoda T, Idani H, Gochi A, Orita K.
    Acta Med Okayama; 1993 Apr; 47(2):79-84. PubMed ID: 8506753
    [Abstract] [Full Text] [Related]

  • 2. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M, Kjaergaard J, Kuppen PJ, Nannmark U, Agger R, Hokland P, Basse P.
    In Vivo; 1999 Apr; 13(3):199-204. PubMed ID: 10459491
    [Abstract] [Full Text] [Related]

  • 3. Cure of B16F10 melanoma lung metastasis in mice by chronic indomethacin therapy combined with repeated rounds of interleukin 2: characteristics of killer cells generated in situ.
    Lala PK, Parhar RS.
    Cancer Res; 1988 Mar 01; 48(5):1072-9. PubMed ID: 3124954
    [Abstract] [Full Text] [Related]

  • 4. Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide.
    Goldfarb RH, Ohashi M, Brunson KW, Kirii Y, Kotera Y, Basse PH, Kitson RP.
    Anticancer Res; 1998 Mar 01; 18(3A):1441-6. PubMed ID: 9673353
    [Abstract] [Full Text] [Related]

  • 5. Development of an interleukin-2 slow delivery system.
    Matsuoka J, Sakagami K, Shiozaki S, Uchida S, Fujiwara T, Gohchi A, Orita K.
    ASAIO Trans; 1988 Mar 01; 34(3):729-31. PubMed ID: 3264177
    [Abstract] [Full Text] [Related]

  • 6. Tumor blood supply and tumor localization by adoptively transferred IL-2 activated natural killer cells.
    Nannmark U, Hokland ME, Agger R, Christiansen M, Kjaergaard J, Goldfarb RH, Bagge U, Unger M, Johansson BR, Albertsson PA, Basse PH.
    In Vivo; 2000 Mar 01; 14(5):651-8. PubMed ID: 11125549
    [Abstract] [Full Text] [Related]

  • 7. Adoptive immunotherapy of intracerebral metastases in mice.
    McCutcheon IE, Baranco RA, Katz DA, Saris SC.
    J Neurosurg; 1990 Jan 01; 72(1):102-9. PubMed ID: 2294169
    [Abstract] [Full Text] [Related]

  • 8. Enhancement of therapeutic effect of interleukin-2 on spontaneous pulmonary metastases of Lewis lung carcinoma by killer helper factor associated with increased induction of killer activity.
    Fukuta K, Sone S, Kitahara M, Okada M, Ogura T.
    Jpn J Cancer Res; 1989 Jun 01; 80(6):562-7. PubMed ID: 2503476
    [Abstract] [Full Text] [Related]

  • 9. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
    Yasumura S, Lin WC, Hirabayashi H, Vujanovic NL, Herberman RB, Whiteside TL.
    Cancer Res; 1994 Jul 15; 54(14):3808-16. PubMed ID: 8033100
    [Abstract] [Full Text] [Related]

  • 10. Augmentation of antitumor effect on syngeneic murine solid tumors by an interleukin 2 slow delivery system, the IL-2 mini-pellet.
    Fujiwara T, Sakagami K, Matsuoka J, Shiozaki S, Fujioka K, Takada Y, Uchida S, Onoda T, Orita K.
    Biotherapy; 1991 Jul 15; 3(3):203-9. PubMed ID: 1854589
    [Abstract] [Full Text] [Related]

  • 11. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A, Tzehoval E, Vadai E, Feldman M, Eisenbach L.
    Cancer Res; 1995 Nov 01; 55(21):4941-9. PubMed ID: 7585534
    [Abstract] [Full Text] [Related]

  • 12. Antitumor effects of a new interleukin-2 slow delivery system on methylcholanthrene-induced fibrosarcoma in mice.
    Fujiwara T, Sakagami K, Orita K.
    J Cancer Res Clin Oncol; 1990 Nov 01; 116(2):141-8. PubMed ID: 2324156
    [Abstract] [Full Text] [Related]

  • 13. Role of cytokines in the adoptive immunotherapy of an experimental model of human head and neck cancer by human IL-2-activated natural killer cells.
    Rabinowich H, Vitolo D, Altarac S, Herberman RB, Whiteside TL.
    J Immunol; 1992 Jul 01; 149(1):340-9. PubMed ID: 1535088
    [Abstract] [Full Text] [Related]

  • 14. Administration of slowly released recombinant interleukin 2. Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells.
    Nishimura T, Uchiyama Y, Yagi H, Hashimoto Y.
    J Immunol Methods; 1986 Jul 11; 91(1):21-7. PubMed ID: 3487591
    [Abstract] [Full Text] [Related]

  • 15. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
    Ettinghausen SE, Rosenberg SA.
    Cancer Res; 1986 Jun 11; 46(6):2784-92. PubMed ID: 3486038
    [Abstract] [Full Text] [Related]

  • 16. [Combined effect of adoptive immunotherapy (AIT) with lymphokine-activated killer (LAK) cells and interleukin-2 (IL-2) and chemotherapy in tumor-bearing mice].
    Yamano Y, Yoshimura A, Shibuya M, Kudoh S.
    Nihon Ika Daigaku Zasshi; 1997 Jun 11; 64(3):211-9. PubMed ID: 9217363
    [Abstract] [Full Text] [Related]

  • 17. Adoptive immunotherapy of human pancreatic cancer with lymphokine-activated killer cells and interleukin-2 in a nude mouse model.
    Marincola FM, Da Pozzo LF, Drucker BJ, Holder WD.
    Surgery; 1990 Nov 11; 108(5):919-29. PubMed ID: 2237773
    [Abstract] [Full Text] [Related]

  • 18. In vivo activation of natural killer cells and priming of IL-2 responsive cytolytic cells by loxoribine (7-allyl-8-oxoguanosine).
    Pope BL, Chourmouzis E, Sigindere J, MacIntyre JP, Capetola RJ, Lau CY.
    Cell Immunol; 1993 Apr 01; 147(2):302-12. PubMed ID: 8453674
    [Abstract] [Full Text] [Related]

  • 19. Natural killer cells inhibit the development of autoantibody production in (C57BL/6 x DBA/2) F1 hybrid mice injected with DBA/2 spleen cells.
    Harada M, Lin T, Kurosawa S, Maeda T, Umesue M, Itoh O, Matsuzaki G, Nomoto K.
    Cell Immunol; 1995 Mar 01; 161(1):42-9. PubMed ID: 7867084
    [Abstract] [Full Text] [Related]

  • 20. Induction and persistence in vivo of NK/LAK activity by a mannoprotein component of Candida albicans cell wall.
    Scaringi L, Cornacchione P, Rosati E, Fettucciari K, Rossi R, Marconi P.
    Cell Immunol; 1994 May 01; 155(2):265-82. PubMed ID: 8181065
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.